Robert B. Carter
Known title: DirectorCIK: 0001197607
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
FedEx eyes record-high Q4 delivery prices and expands digital pharma booking. FedEx expects delivery rates to reach record highs in the fourth quarter, according to a TD Cowen/AFS note. The company says its recent freight‑spin strategy has improved performance, though pricing is still relatively high. It also launched a digital booking platform for European cold‑chain pharmaceutical shipments to make the process smoother for customers.
Transaction History
| DGX | ▼ Sell | Other | 11 | $2K | 7/22/2026 | View on chart |
| DGX | ▲ Buy | Grant | 1,142 | $0 | 5/20/2026 | View on chart |
| DGX | ▼ Sell | Other | 7 | $1K | 4/20/2026 | View on chart |
| DGX | ▼ Sell | Other | 6 | $1K | 1/28/2026 | View on chart |
| DGX | ▲ Buy | Grant | 6 | $1K | 10/21/2025 | View on chart |
| DGX | ▼ Sell | Other | 7 | $1K | 7/21/2025 | View on chart |
| DGX | ▲ Buy | Grant | 1,203 | $0 | 5/15/2025 | View on chart |
| FDX | ▲ Buy | Option Exercise | 16,010 | $2.9M | 6/28/2024 | View on chart |
| FDX | ▼ Sell | Open Market | 16,010 | $4.7M | 6/28/2024 | View on chart |
| FDX | ▲ Buy | Grant | 1,009 | $0 | 6/27/2024 | View on chart |
| DGX | ▲ Buy | Grant | 1,482 | $0 | 5/16/2024 | View on chart |
| FDX | ▲ Buy | Option Exercise | 19,270 | $2.8M | 6/28/2023 | View on chart |
| FDX | ▼ Sell | Open Market | 19,270 | $4.7M | 6/28/2023 | View on chart |
| FDX | ▲ Buy | Grant | 3,959 | $0 | 6/22/2023 | View on chart |
| FDX | ▲ Buy | Option Exercise | 12,310 | $1.2M | 7/26/2022 | View on chart |
| FDX | ▼ Sell | Open Market | 12,310 | $2.8M | 7/26/2022 | View on chart |
| FDX | ▲ Buy | Option Exercise | 12,310 | $1.2M | 7/8/2022 | View on chart |
| FDX | ▼ Sell | Open Market | 12,310 | $2.8M | 7/8/2022 | View on chart |
| FDX | ▲ Buy | Grant | 4,005 | $0 | 6/30/2022 | View on chart |
| FDX | ▼ Sell | Gift | 100 | $0 | 12/27/2021 | View on chart |
| FDX | ▼ Sell | Gift | 758 | $0 | 12/22/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus
Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus. Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.